vs

Side-by-side financial comparison of Avidity Biosciences, Inc. (RNA) and WINMARK CORP (WINA). Click either name above to swap in a different company.

WINMARK CORP is the larger business by last-quarter revenue ($21.1M vs $12.5M, roughly 1.7× Avidity Biosciences, Inc.). WINMARK CORP runs the higher net margin — 47.2% vs -1398.3%, a 1445.6% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 7.9%). WINMARK CORP produced more free cash flow last quarter ($8.5M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 2.4%).

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

Winmark Corporation is an American franchisor of five retail businesses that specialize in buying and selling used goods. The company is based in Minneapolis, Minnesota. Winmark was founded in 1988 as Play It Again Sports Franchise Corporation by Ron Olson and Jeffrey Dahlberg after they purchased the Play It Again Sports franchise rights from Martha Morris. They renamed the company to Grow Biz International Inc. in June 1993. Grow Biz went public in August 1993. In 2000, John Morgan replaced...

RNA vs WINA — Head-to-Head

Bigger by revenue
WINA
WINA
1.7× larger
WINA
$21.1M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+426.2% gap
RNA
434.0%
7.9%
WINA
Higher net margin
WINA
WINA
1445.6% more per $
WINA
47.2%
-1398.3%
RNA
More free cash flow
WINA
WINA
$165.4M more FCF
WINA
$8.5M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
2.4%
WINA

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
RNA
RNA
WINA
WINA
Revenue
$12.5M
$21.1M
Net Profit
$-174.4M
$10.0M
Gross Margin
Operating Margin
-1513.5%
61.7%
Net Margin
-1398.3%
47.2%
Revenue YoY
434.0%
7.9%
Net Profit YoY
-117.0%
3.9%
EPS (diluted)
$-1.27
$2.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RNA
RNA
WINA
WINA
Q4 25
$21.1M
Q3 25
$12.5M
$22.6M
Q2 25
$3.8M
$20.4M
Q1 25
$1.6M
$21.9M
Q4 24
$3.0M
$19.5M
Q3 24
$2.3M
$21.5M
Q2 24
$2.0M
$20.1M
Q1 24
$3.5M
$20.1M
Net Profit
RNA
RNA
WINA
WINA
Q4 25
$10.0M
Q3 25
$-174.4M
$11.1M
Q2 25
$-157.3M
$10.6M
Q1 25
$-115.8M
$10.0M
Q4 24
$-102.3M
$9.6M
Q3 24
$-80.4M
$11.1M
Q2 24
$-70.8M
$10.4M
Q1 24
$-68.9M
$8.8M
Operating Margin
RNA
RNA
WINA
WINA
Q4 25
61.7%
Q3 25
-1513.5%
65.9%
Q2 25
-4448.7%
64.0%
Q1 25
-8360.9%
62.0%
Q4 24
-4069.6%
65.3%
Q3 24
-4200.9%
69.4%
Q2 24
-4040.4%
64.7%
Q1 24
-2178.6%
60.8%
Net Margin
RNA
RNA
WINA
WINA
Q4 25
47.2%
Q3 25
-1398.3%
49.2%
Q2 25
-4089.3%
51.9%
Q1 25
-7360.0%
45.4%
Q4 24
-3439.5%
49.0%
Q3 24
-3441.7%
51.7%
Q2 24
-3461.8%
51.8%
Q1 24
-1943.4%
43.9%
EPS (diluted)
RNA
RNA
WINA
WINA
Q4 25
$2.68
Q3 25
$-1.27
$3.02
Q2 25
$-1.21
$2.89
Q1 25
$-0.90
$2.71
Q4 24
$-0.80
$2.60
Q3 24
$-0.65
$3.03
Q2 24
$-0.65
$2.85
Q1 24
$-0.79
$2.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RNA
RNA
WINA
WINA
Cash + ST InvestmentsLiquidity on hand
$350.2M
$10.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$-53.7M
Total Assets
$2.1B
$24.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RNA
RNA
WINA
WINA
Q4 25
$10.3M
Q3 25
$350.2M
$39.7M
Q2 25
$243.9M
$28.8M
Q1 25
$254.2M
$21.8M
Q4 24
$219.9M
$12.2M
Q3 24
$370.2M
$37.2M
Q2 24
$575.8M
$29.4M
Q1 24
$471.4M
$22.9M
Stockholders' Equity
RNA
RNA
WINA
WINA
Q4 25
$-53.7M
Q3 25
$1.9B
$-26.3M
Q2 25
$1.2B
$-36.8M
Q1 25
$1.3B
$-45.9M
Q4 24
$1.4B
$-51.0M
Q3 24
$1.5B
$-33.7M
Q2 24
$1.2B
$-42.2M
Q1 24
$830.9M
$-52.6M
Total Assets
RNA
RNA
WINA
WINA
Q4 25
$24.9M
Q3 25
$2.1B
$53.7M
Q2 25
$1.4B
$43.2M
Q1 25
$1.5B
$37.1M
Q4 24
$1.6B
$26.8M
Q3 24
$1.6B
$52.0M
Q2 24
$1.3B
$44.7M
Q1 24
$951.5M
$38.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RNA
RNA
WINA
WINA
Operating Cash FlowLast quarter
$-156.2M
$8.5M
Free Cash FlowOCF − Capex
$-156.9M
$8.5M
FCF MarginFCF / Revenue
-1257.6%
40.3%
Capex IntensityCapex / Revenue
5.7%
0.1%
Cash ConversionOCF / Net Profit
0.86×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M
$44.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RNA
RNA
WINA
WINA
Q4 25
$8.5M
Q3 25
$-156.2M
$12.3M
Q2 25
$-199.7M
$9.0M
Q1 25
$-124.8M
$15.1M
Q4 24
$-99.9M
$8.5M
Q3 24
$-65.6M
$12.1M
Q2 24
$-65.0M
$8.2M
Q1 24
$-70.4M
$13.4M
Free Cash Flow
RNA
RNA
WINA
WINA
Q4 25
$8.5M
Q3 25
$-156.9M
$12.2M
Q2 25
$-203.0M
$9.0M
Q1 25
$-128.6M
$15.0M
Q4 24
$-103.8M
Q3 24
$-67.3M
$12.1M
Q2 24
$-65.5M
$8.1M
Q1 24
$-71.3M
$13.3M
FCF Margin
RNA
RNA
WINA
WINA
Q4 25
40.3%
Q3 25
-1257.6%
53.8%
Q2 25
-5277.1%
44.0%
Q1 25
-8174.3%
68.6%
Q4 24
-3491.0%
Q3 24
-2881.8%
56.3%
Q2 24
-3204.6%
40.4%
Q1 24
-2012.3%
66.0%
Capex Intensity
RNA
RNA
WINA
WINA
Q4 25
0.1%
Q3 25
5.7%
0.3%
Q2 25
86.9%
0.3%
Q1 25
238.6%
0.2%
Q4 24
131.7%
0.0%
Q3 24
72.9%
0.0%
Q2 24
26.0%
0.5%
Q1 24
25.8%
0.4%
Cash Conversion
RNA
RNA
WINA
WINA
Q4 25
0.86×
Q3 25
1.10×
Q2 25
0.85×
Q1 25
1.51×
Q4 24
0.88×
Q3 24
1.09×
Q2 24
0.79×
Q1 24
1.52×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons